NEW YORK (GenomeWeb News) – Response Biomedical today reported that its third-quarter revenues rose 39 percent, while its net loss fell around 14 percent.

The genetic test maker brought in revenues of C$2 million (US$1.9 million) for the three-month period ended Sept. 30, compared to revenues of C$1.5 million in the period last year.

Most of that revenue boost came from the firm’s clinical products business, which increased 62 percent to around C$1.7 million compared with approximately C$1 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.